Market Overview

UPDATE: Bank of America Raises PT to $70 on Baxter International; Gambro Strategic Fit at Steep Price

Share:
Related BAX
How Altimmune Is Trying To Get Ahead Of A Potentially Fatal 'Flu Pandemic'
Baxter (BAX) Scales 52-Week High: What's Behind the Rally

Bank of America reiterated its Buy rating on Baxter International (NYSE: BAX) and increased its price target from $67 to $70.

Bank of America commented, "On Friday the Wall Street Journal and several other media outlets reported that BAX is in talks to acquire privately held Gambro for $4bn (BAX's market cap is $38bn). Gambro is the #2 share player in the hemodialysis technology market where BAX has little presence, and BAX is #1 in the peritoneal dialysis market where Gambro has no presence. In our view, in the hands of BAX, Gambro would be a much tougher HD competitor and a strong strategic fit, with the potential for significant synergies, but a $4bn price tag creates a very high hurdle for positive returns in our view."

Baxter International closed at $67.18 on Friday.

Latest Ratings for BAX

DateFirmActionFromTo
May 2017Goldman SachsInitiates Coverage OnBuy
Oct 2016Wells FargoInitiates Coverage OnOutperform
Sep 2016BarclaysInitiates Coverage onOverweight

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BAX)

View Comments and Join the Discussion!